Immunic, inc. (VTL)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating expenses:
Research and development

22,512

9,595

39,341

30,046

39,773

39,479

21,787

5,097

General and administrative

14,520

2,402

13,314

11,220

12,347

10,863

9,615

4,483

Severance costs

-

-

0

0

-

-

-

-

Impairment of Long-Lived Assets Held-for-use

-

-

0

0

-

-

-

-

Total operating expenses

37,032

11,997

52,655

41,266

52,120

50,342

31,402

9,580

Loss from operations

-37,032

-11,997

-52,655

-41,266

-52,120

-50,342

-31,402

-9,580

Other income (expense):
Interest income (expense)

-

1

-

-

-

-

-

-

Interest income

107

-

650

284

58

19

5

4

Interest expense

-

-

-

-

-

-

-

413

Other income, net

1,992

456

-73

13

39

56

-15

7

Revaluation of preferred stock warrant liabilities

-

-

-

-

-

-

-

180

Revaluation of future purchase rights liabilities

-

-

-

-

-

2,600

-1,306

3,101

Total other income

2,099

455

577

297

97

2,675

-1,316

2,879

Net loss

-34,933

-11,542

-52,078

-40,969

-52,023

-47,667

-32,718

-6,701

Amortization of deemed dividend

-

-

-

-

-

4,744

64

-

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

4,410

6,303

942

Net loss attributable to common stockholders

-

-

-

-

-

-56,821

-39,085

-7,643

Net loss per share, basic and diluted (in USD per share)

-4.52

-13.63

-1.31

-1.31

-2.07

-3.54

-74.86

-17.89

Weighted-average common shares outstanding, basic and diluted (in shares)

7,722

846

39,859

31,387

25,152

16,054

522

427